Metabolomics approach discriminates toxicity index of pyrazinamide and its metabolic products, pyrazinoic acid and 5-hydroxy pyrazinoic acid

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Human and Experimental Toxicology

• Publication date

  2018-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1177/0960327117705426PMID 28425350
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel Indole-fused benzo-oxazepines (IFBOs) inhibit invasion of hepatocellular carcinoma by targeting IL-6 mediated JAK2/STAT3 oncogenic signals

  2018cited by this paper
• Pyrazinamide-induced hepatotoxicity and gender differences in rats as revealed by a 1H NMR based metabolomics approach.

  2017cited by this paper
• The Burden of Drug-Resistant Tuberculosis in Papua New Guinea: Results of a Large Population-Based Survey

  2016cited by this paper
• 1H NMR-based serum metabolomics reveals erythromycin-induced liver toxicity in albino Wistar rats

  2016cited by this paper
• Biochemical characterization of blood plasma of coronary artery disease patients by in vitro high-resolution proton NMR spectroscopy

  2015cited by this paper
• Antidiabetic effects of isolated sterols from Ficus racemosa leaves

  2015cited by this paper
• MetaboAnalyst 3.0—making metabolomics more meaningful

  2015cited by this paper
• Chemical Shifts to Metabolic Pathways: Identifying Metabolic Pathways Directly from a Single 2D NMR Spectrum.

  2015cited by this paper
• The Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role?

  2015cited by this paper
• Drug-induced liver injury: the dawn of biomarkers?

  2015cited by this paper
• Lipid and Lipoprotein Metabolism in Liver Disease

  2015cited by this paper
• Oxidative stress as a crucial factor in liver diseases.

  2014cited by this paper
• Metabolite characterisation in peritoneal dialysis effluent using high‐resolution 1H and 1H–13C NMR spectroscopy

  2014cited by this paper
• Olfactory disturbance related to pyrazinamide.

  2014cited by this paper
• A Novel Mechanism Underlies the Hepatotoxicity of Pyrazinamide

  2013cited by this paper
• Metabolic signatures of esophageal cancer: NMR-based metabolomics and UHPLC-based focused metabolomics of blood serum.

  2013cited by this paper
• Gene expression profiling reveals potential key pathways involved in pyrazinamide‐mediated hepatotoxicity in Wistar rats

  2013cited by this paper
• Evaluation of mechanism of hepatotoxicity of leflunomide using albino wistar rats

  2013cited by this paper
• Citrate Pharmacokinetics in Critically Ill Patients with Acute Kidney Injury

  2013cited by this paper
• A review of the important central role of altered citrate metabolism during the process of stem cell differentiation.

  2013cited by this paper
• Differentiating Hepatocellular Carcinoma from Hepatitis C Using Metabolite Profiling

  2012cited by this paper
• Pyrrolidinediones reduce the toxicity of thiazolidinediones and modify their anti-diabetic and anti-cancer properties.

  2012cited by this paper
• HMDB 3.0—The Human Metabolome Database in 2013

  2012cited by this paper
• Plasma metabolomic profile in nonalcoholic fatty liver disease.

  2011cited by this paper
• Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst

  2011cited by this paper
• Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling.

  2011cited by this paper
• Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study

  2011cited by this paper
• Creatine as an antioxidant

  2011cited by this paper
• Direct toxicity effects of sulfo-conjugated troglitazone on human hepatocytes.

  2010cited by this paper
• Monitoring liver alterations during hepatic tumorigenesis by NMR profiling and pattern recognition

  2010cited by this paper
• The relationship between lipid profile and severity of liver damage in cirrhotic patients

  2010cited by this paper
• Protein Carbonylation

  2010cited by this paper
• NMR metabolomics and drug discovery

  2009cited by this paper
• Amino acids: metabolism, functions, and nutrition

  2009cited by this paper
• MetaboAnalyst: a web server for metabolomic data analysis and interpretation

  2009cited by this paper
• Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management.

  2009cited by this paper
• Creatine synthesis: hepatic metabolism of guanidinoacetate and creatine in the rat in vitro and in vivo.

  2009cited by this paper
• Metabolic changes in flatfish hepatic tumours revealed by NMR-based metabolomics and metabolic correlation networks.

  2008cited by this paper
• Metabolomics: a global biochemical approach to drug response and disease.

  2008cited by this paper
• Clinical use of glutamine supplementation.

  2008cited by this paper
• Evaluation of Population Pharmacokinetics and Exposure‐Response Relationship With Coadministration of Amlodipine Besylate and Olmesartan Medoxomil

  2008cited by this paper
• Anti-tuberculosis medication side-effects constitute major factor for poor adherence to tuberculosis treatment.

  2008cited by this paper
• Isoniazid and its toxic metabolite hydrazine induce in vitro pyrazinamide toxicity.

  2008cited by this paper
• Antituberculosis drug‐induced hepatotoxicity: Concise up‐to‐date review

  2008cited by this paper
• Global metabolic profiling and its role in systems biology to advance personalized medicine in the 21st Century

  2007cited by this paper
• Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities.

  2007cited by this paper
• The influence of fatty acids on model cholesterol/phospholipid membranes.

  2007cited by this paper
• Spectrum of Liver Disease in Type 2 Diabetes and Management of Patients With Diabetes and Liver Disease

  2007cited by this paper
• Hepatic damage in biliary-obstructed rats is ameliorated by leflunomide treatment

  2006cited by this paper
• Experimental metabonomic model of dietary variation and stress interactions.

  2006cited by this paper
• Distribution and function of biogenic amines in the heart of Nautilus pompilius L. (Cephalopoda, Tetrabranchiata)

  2005cited by this paper
• Performance of some variable selection methods when multicollinearity is present

  2005cited by this paper
• Determination and pharmacokinetic profile of pyrazinamide in rat blood, brain and bile using microdialysis coupled with high-performance liquid chromatography and verified by tandem mass spectrometry

  2004cited by this paper
• Role of the liver in the control of carbohydrate and lipid homeostasis.

  2004cited by this paper
• Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects

  2004cited by this paper
• A metabonomic investigation of hepatotoxicity using diffusion-edited 1H NMR spectroscopy of blood serum.

  2003cited by this paper
• Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients

  2003cited by this paper
• Raised plasma total sialic acid levels are markers of cardiovascular disease in renal dialysis patients.

  2003cited by this paper
• Novel concepts in insulin regulation of hepatic gluconeogenesis.

  2003cited by this paper
• Use of 1H NMR‐determined diffusion coefficients to characterize lipoprotein fractions in human blood plasma

  2002cited by this paper
• Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis.

  2002cited by this paper
• Glycemic homeostasis in chronic viral hepatitis and liver cirrhosis.

  2001cited by this paper
• Liver disease and diabetes mellitus.

  2001cited by this paper
• Actions of Melatonin in the Reduction of Oxidative Stress

  2000cited by this paper
• Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.

  2000cited by this paper
• Detection of low density lipoprotein particle fusion by proton nuclear magnetic resonance spectroscopy.

  1998cited by this paper
• Prevention of lipid peroxidation induced by ochratoxin A in Vero cells in culture by several agents.

  1997cited by this paper
• Hepatotoxicity of Antitubercular Treatments

  1996cited by this paper
• 750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma.

  1995cited by this paper
• Clinical significance of measuring plasma concentrations of glutamine and glutamate in alcoholic liver diseases.

  1993cited by this paper
• Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.

  1990cited by this paper
• Handbook of Methods for Oxygen Radical Research

  1988cited by this paper
• Tissue levels of bilirubin and biliverdin in the sea lamprey, Petromyzon marinus L., before and after biliary atresia.

  1988cited by this paper
• Glutamic acid and glutamine levels in serum and cerebrospinal fluid in hepatic encephalopathy.

  1984cited by this paper
• Mitochondrial metabolism of glutamine and glutamate and its physiological significance.

  1983cited by this paper
• Synthesis and regulation of acute phase plasma proteins in primary cultures of mouse hepatocytes

  1983cited by this paper
• The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide.

  1977cited by this paper

• Formulation of Surface-Modified Quercetin-Loaded Chitosan-Hyaluronic Acid Nanoparticles for Targeted Hepatic Cancer Therapy

  2026cites this paper
• Pyrazinamide-induced hepatotoxicity mediated by aldehyde oxidase and xanthine oxidase.

  2026cites this paper
• A scoping review about smoking, smoking cessation and their effects on anti-tuberculosis agents: insights into drug metabolisms, safety, and effectiveness

  2025cites this paper
• Mitigating Tuberculosis Drug-induced Liver Injury: The Role of Moringa oleifera and Other Herbal Extracts.

  2025cites this paper
• Chitosan-Folic Acid-Coated Quercetin-Loaded PLGA Nanoparticles for Hepatic Carcinoma Treatment

  2025cites this paper
• Hepatic safety of pretomanid- and pyrazinamide-containing regimens in TB Alliance clinical trials

  2025cites this paper
• Effects of adenosine triphosphate, thiamine pyrophosphate, melatonin, and liv-52 on subacute pyrazinamide proliferation hepatotoxicity in rats

  2025cites this paper
• Advances in Antituberculosis Drug-induced Liver Injury: Molecular Mechanisms, Genetic Insights, and Emerging Animal-Free Prediction Models.

  2025cites this paper
• Progress in Research on Hepatic Injury Caused by Anti-Tuberculosis Drugs

  2024cites this paper
• Cooperative STAT3-NFkB signaling modulates mitochondrial dysfunction and metabolic profiling in hepatocellular carcinoma.

  2024cites this paper
• Antitubercular drugs induced liver injury: an updated insight into molecular mechanisms

  2023cites this paper
• Pharmacokinetic Assessment of Pyrazinamide and Pyrazinoic Acid in Carbon tetrachloride-induced Liver Injury Model in Wistar Rats

  2023cites this paper
• Hepatoprotective effects of natural drugs: Current trends, scope, relevance and future perspectives.

  2023cites this paper
• Hyperuricemia, use of antituberculosis drugs, and liver injury: case report

  2023cites this paper
• SARS-CoV-2-mediated liver injury: pathophysiology and mechanisms of disease

  2022cites this paper
• Urine metabolomics and microbiome analyses reveal the mechanism of anti-tuberculosis drug-induced liver injury, as assessed for causality using the updated RUCAM: A prospective study

  2022cites this paper
• The role of the farnesoid X receptor in quadruple anti-tuberculosis drug-induced liver injury.

  2022cites this paper
• Plasma metabolomic and lipidomic alterations associated with anti-tuberculosis drug-induced liver injury

  2022cites this paper
• Metabolism and Hepatotoxicity of Pyrazinamide, an Antituberculosis Drug

  2021influential citation
• Metabolomics describes previously unknown toxicity mechanisms of isoniazid and rifampicin.

  2020cites this paper
• An Evaluation of the In Vitro Roles and Mechanisms of Silibinin in Reducing Pyrazinamide- and Isoniazid-Induced Hepatocellular Damage

  2019cites this paper
• Additional compounds and the therapeutic potential of Cnidoscolus chayamansa (McVaugh) against hepatotoxicity induced by antitubercular drugs.

  2019cites this paper
• The application of metabolomics toward pulmonary tuberculosis research.

  2019cites this paper
• Novel Indole-fused benzo-oxazepines (IFBOs) inhibit invasion of hepatocellular carcinoma by targeting IL-6 mediated JAK2/STAT3 oncogenic signals

  2018cites this paper
• Novel fused oxazepino‐indoles (FOIs) attenuate liver carcinogenesis via IL‐6/JAK2/STAT3 signaling blockade as evidenced through data‐based mathematical modeling

  2018cites this paper
• Mass spectrometry-based metabolomics for tuberculosis meningitis.

  2018cites this paper
• Novel 1,4‐benzothazines obliterate COX‐2 mediated JAK‐2/STAT‐3 signals with potential regulation of oxidative and metabolic stress during colorectal cancer

  2017cites this paper
• The role of metabolomics in tuberculosis treatment research.

  2017cites this paper